At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 90 enrolled
Drug / intervention
liposomal Bupivacaine +1 moredrug
Likely dose
liposomal Bupivacaine 20 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Liposomal Bupivacaine Versus Standard Bupivacaine Hydrochloride In Colorectal Surgery
In Brief
A Phase 3 clinical trial evaluating liposomal Bupivacaine and Bupivacaine Hydrochloride for Colorectal Surgery. Completed, enrolled 90 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the difference between two different pain control methods in patients who will be having a colorectal surgery
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Surgery
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartAug 2018
First PostedOct 2018
Primary CompletionMar 2020
TodayJul 2026
First PostedOct 11, 2018
Enrollment StartAug 30, 2018
Primary CompletionMar 13, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.7 years ago
Interventions
liposomal Bupivacainedrug
20 mL liposomal bupivacaine are injected into the liposomal bupivacaine group
Bupivacaine Hydrochloridedrug
40 mL of 0.125% bupivacaine hydrochloride are injected into the liposomal bupivacaine group. 60mL of 0.25% bupivacaine hydrochloride are injected into the standard bupivacaine group